Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use

AIDS

Volumn 14, Issue 2, 2000, Pages

  Salomon, Horacio ^f   Wainberg, Mark A ^e   Brenner, Bluma ^g   Quan, Yudong ^g   Rouleau, Danielle ^a   Coté, Pierre ^a   LeBlanc, Roger ^a   Lefebvre, Eric ^a   Spira, Bonnie ^g   Tsoukas, Chris ^a   Sekaly, Rafik Pierre ^a   Conway, Brian ^b   Mayers, Douglas ^c   Routy, Jean Pierre ^d  

^a Fonds de la Recherche en Sante du Quebec   (Canada)

^b Viridae Clinical Sciences Inc   (Canada)

^c HENRY FORD HOSPITAL   (United States)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^g NONE

Author keywords

Antiretroviral therapy; HIV drug resistance; Protease inhibitors; Resistance mutations; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CODON; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VIRUS ISOLATION;

ANTI-HIV AGENTS; CANADA; CODON; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LONGITUDINAL STUDIES; MALE; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0002035867     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00003     Document Type: Article

References (21)

1. 1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. 2. Wainberg MA, Friedland G. Public health implications of anti-retroviral therapy and HIV drug resistance. JAMA 1999, 279:1977-1983.
3. 3. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998, 279:1984-1991.
4. 4. Schinazi R, Larder B, Mellors J. Mutations in retroviral genes associated in drug resistance. Int. Antiviral News 1997, 5:129-142.
5. 5. Condra J. Virologic and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist Updates 1998, 1:292-299.
6. 6. Esnouf R, Ren J, Ross C, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct Biol 1995, 2:303-308.
7. 7. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163-1165.
8. 8. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. New Engl J Med 1999, 339:307-311.
9. 9. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS 1994, 8:1013-1014.
10. 10. Imrie A, Beveridge A, Genn W, Vizzard J, and Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Croup. J Infect Dis 1997, 175:1502-1506.
11. 11. Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus - the wakeup call. N Engl J Med 1998, 339:341-343.
12. 12. Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ. Mutations associated with zidovudine resistance in HIV-1 among recent seroconverters. AIDS 1997, 11:835-836.
13. 13. de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands [letter]. AIDS 1996; 10:231-232.
14. R) HIV-1 Persons Seroconverting in Switzerland, Australia, and the United States Between 1988 and 1994. 34th Interscience Conference on Antimicrobial Agents and chemotherapy. Orlando, October 1994 [abstract A/11].
15. 15. Yerly S, Kaiser L, Race E, Bru J-P, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
16. 16. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
17. 17. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary infection. JAMA 1999, 282:1142-1149.
18. 18. Salomon H, Belmonte A, Nguyen K, Gu Z, Gelfand M, Wainberg MA. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J Clin Microbiol. 1994, 32:2000-2002.
19. 19. Boulerice F, Bour S, Geleziunas R, Lvovitch A, Wainberg MA. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol 1990, 64:1745-1755.
20. 20. Gao Q, Gu Z, Parniak MA, Li X, Wainberg MA. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J Virol 1992, 66:12-19.
21. 21. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997, 41:284-291.